---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-146091"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:53:34.719227+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AlloVir stockholder vote approves doubling authorized common shares to 300M

## Summary
- Charter amendment filed May 15 increases authorized common from 150M to 300M shares.
- Proposal 3 approved: 86,571,410 for, 544,049 against, 1,225 abstain.
- Class III directors elected: Bornstein, Brainard, Hallal, Tomasello; vote totals provided.
- Ratification of Deloitte & Touche as auditor for FY2023 approved: 86,411,460 for.
- Record date March 15, 2023; 93,511,558 shares outstanding and entitled to vote.

## SEC filing metadata
- accession: 0001193125-23-146091
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312523146091/0001193125-23-146091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312523146091/d468524d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-146091
- JSON: https://secwatch.observer/filing/0001193125-23-146091.json
- Plain text: https://secwatch.observer/filing/0001193125-23-146091.txt

## Key facts
- Governance Changes
  Kalaris Therapeutics, Inc.: Increased authorized shares of common stock from 150,000,000 to 300,000,000 (effective 2023-05-15).
  - Change: charter amendment
  - Effective: 2023-05-15
  source text: On May 15, 2023, AlloVir, Inc. (the “Company”) filed a certificate of amendment to its amended and restated certificate of incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware to increase the authorized shares of common stock from 150,000,000 to 300,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523146091/0001193125-23-146091-index.htm
- Shareholder Votes
  Kalaris Therapeutics, Inc. shareholders approved Election of Class III directors: Jeffrey Bornstein, Diana Brainard, M.D., David Hallal, Shawn Tomasello at the 2023-05-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-11
  source text: The Company’s stockholders approved the Class III director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for the Class III directors as follows: Class III Director Nominee For Withhold Broker Non- Votes Jeffrey Bornstein 51,184,647 11,888,021 24,044,016 Diana Brainard, M.D. 54,972,729 8,099,939 24,044,016 David Hallal 54,298,062 8,774,606 24,044,016 Shawn Tomasello 51,020,208 12,052,460 24,044,016
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523146091/0001193125-23-146091-index.htm
- Shareholder Votes
  Kalaris Therapeutics, Inc. shareholders approved Amendment to Third Amended and Restated Certificate of Incorporation to increase authorized common shares from 150,000,000 to 300,000,000 at the 2023-05-11 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-05-11
  source text: For Against Abstain 86,571,410 544,049 1,225
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523146091/0001193125-23-146091-index.htm
- Shareholder Votes
  Kalaris Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-11
  source text: For Against Abstain 86,411,460 689,359 15,865
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523146091/0001193125-23-146091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.